Table 1 Sample information.
From: RBM47 is a novel immunotherapeutic target and prognostic biomarker in gliomas
Characteristics (CGGA2022) | Patients (n = 325) | Characteristics (TCGA) | Patients = 702 |
|---|---|---|---|
Gender | Gender | ||
 Male | 203 |  Male | 354 |
 Female | 122 |  Female | 255 |
WHO grade | Â NA | 93 | |
 Grade II | 103 | WHO grade | |
 Grade III | 79 |  Grade II | 216 |
 Grade IV | 139 |  Grade III | 241 |
 NA | 4 |  Grade IV | 152 |
IDH status | Â NA | 93 | |
 Mutation | 175 | IDH status | |
 Wildtype | 149 |  Mutation | 428 |
 NA | 1 |  Wildtype | 234 |
1p/19q status | Â NA | 40 | |
 Codeletion | 67 | 1p/19q status | |
 Non-codeletion | 250 |  Codeletion | 169 |
 NA | 8 |  Non-codeletion | 495 |
MGMT status | Â NA | 38 | |
 Methylation | 157 | MGMT status | |
 Unmethylation | 149 |  Methylation | 492 |
 NA | 19 |  Unmethylation | 168 |
| Â | Â | Â NA | 42 |
